Results 251 to 260 of about 118,264 (311)

Neurovascular Uncoupling in Alzheimer's and Parkinson's Diseases: Mechanisms and Therapeutic Strategies. [PDF]

open access: yesBrain Sci
Ved A   +11 more
europepmc   +1 more source

Vasodilators

Reactions Weekly, 2014
Abstract The vasodilator combination of hydralazine and isosorbide dinitrate may be considered as an alternative to an ACE inhibitor or ARB, if neither is tolerated, to reduce the risk of HF hospitalization and risk of premature death in patients with chronic heart failure secondary to LVSD. This chapter describes the pharmacology and
Roy S. Gardner   +2 more
  +4 more sources

Mechanisms of vasodilation

The American Journal of Medicine, 1983
Abstract A variety of factors interact to regulate vascular tone and thereby control blood flow to the regional circulations. The influx of calcium into vascular smooth muscle initiates contraction by binding to calmodulin and stimulating myosin light chain kinase.
openaire   +2 more sources

Vasodilator therapy

The American Journal of Medicine, 1986
Vasodilators are a group of drugs with various degrees of arteriolar or venous dilatation used in the treatment of congestive heart failure when symptoms persist after digoxin and diuretic therapy. Nitrates and captopril provide the most consistent improvement in symptoms. Reduced mortality rates in congestive heart failure with vasodilator therapy has
openaire   +2 more sources

Pulmonary Vasodilators

Respiratory Care, 2007
Pulmonary vasodilators are an important treatment for pulmonary arterial hypertension. They reduce pulmonary artery pressure; improve hemodynamic function; alter ventilation/perfusion matching in the lungs; and improve functional quality of life, exercise tolerance, and survival in patients with severe pulmonary arterial hypertension.
openaire   +2 more sources

Vasodilating Therapy

1986
info:eu-repo/semantics ...
openaire   +2 more sources

Vasodilators

Abstract The vasodilator combination of hydralazine and isosorbide dinitrate may be considered as an alternative to an ARNI, ACE inhibitor, or ARB, if they are not tolerated, to reduce the risk of HF hospitalization and risk of premature death in patients with chronic heart failure secondary to LVSD.
Roy S. Gardner   +3 more
openaire   +1 more source

Home - About - Disclaimer - Privacy